Search
News
Harmony Biosciences Q2 2026 earnings: WAKIX revenue rises 30%
Harmony Biosciences reported Q2 2026 WAKIX net product revenue of $261.3 million, up 30% year over year, while diluted EPS rose to $1.28 from $0.68. Net income reached $75.4 million as revenue growth and lower operating expenses outweighed pressure from new Novitium royalties, which narrowed gross margin. The company reiterated full-year WAKIX revenue guidance of $1.0 billion to $1.04 billion and outlined upcoming BP-205 clinical milestones and the April 1, 2027 PDUFA target for pitolisant GR. The quarter combined commercial growth with a heavier product-cost burden.
TradingKey
Wed, Aug 5
Palvella Q2 2026 earnings: R&D spending widens loss as NDA advances
Palvella Therapeutics’ Q2 2026 net loss widened to $21.9 million from $9.5 million, while basic and diluted loss per share increased to $1.52 from $0.86. R&D expense rose to $12.5 million as the company funded manufacturing, angiokeratoma development, its rolling QTORIN rapamycin NDA and additional personnel. Palvella ended June with $250.6 million in cash, cash equivalents and short-term investments while maintaining plans to complete the NDA in the second half of 2026 and launch in the first half of 2027 if approved.
TradingKey
Wed, Aug 5
Thryv Q2 2026 Earnings: SaaS Mix Reaches 76% as Revenue Falls 28%
Thryv’s Q2 2026 revenue fell 28.4% year over year to $150.7 million, while diluted EPS swung to a $0.38 loss from $0.31 in earnings. SaaS revenue slipped 0.5% to $114.5 million but rose to 76% of total revenue as Marketing Services revenue dropped 62%. Adjusted EBITDA declined to $20.8 million, and Thryv announced a $20 million to $25 million restructuring plan targeting $55 million to $60 million in annualized gross savings. Full-year SaaS revenue guidance is $453 million to $457 million.
TradingKey
Wed, Aug 5
FIS Q2 2026 Earnings: Total Issuing Solutions Lifts Revenue and Margins
FIS reported Q2 2026 revenue of $3.377 billion, up 29% year over year, and GAAP diluted EPS of $0.45 versus a $0.90 loss. Adjusted EBITDA rose 35% to $1.409 billion as margin expanded 193 basis points to 41.7%, supported by Total Issuing Solutions, favorable mix, and cost savings. Free cash flow increased 220% to $525 million. However, pro forma revenue growth was 5.3%, and FIS lowered its full-year pro forma revenue and adjusted EBITDA growth ranges while raising its free cash flow target by $100 million.
TradingKey
Wed, Aug 5
Albany International Q2 2026 Earnings: Composites Drive Margin Expansion
Albany International reported Q2 2026 revenue of $329.5 million, up 6% year over year, while diluted GAAP EPS rose to $0.61 from $0.31. Adjusted EBITDA increased 11.5% to $57.8 million as Engineered Composites growth and a more profitable program mix outweighed Machine Clothing softness, equipment downtime, and currency pressure. Consolidated adjusted EBITDA margin expanded to 17.6%, but quarterly free cash flow turned negative as operating cash flow weakened, leaving cash conversion and working-capital trends central to the next quarter.
TradingKey
Wed, Aug 5
NRG Q2 2026 Earnings: EBITDA Rises While Adjusted EPS Falls
NRG Energy’s Q2 2026 revenue increased approximately 11% to $7.481 billion, while diluted GAAP EPS improved to $2.31 from a $0.62 loss. Adjusted EBITDA rose 34% to $1.217 billion as acquired LS Power assets, CPower, and higher East capacity prices more than offset weaker Texas results. However, adjusted EPS declined to $1.49 because of higher interest expense, depreciation and amortization, and acquisition-related share issuance. Quarterly operating cash flow reached $1.117 billion, and NRG reaffirmed its 2026 adjusted earnings and cash-flow guidance.
TradingKey
Wed, Aug 5
Turning Point Brands Q2 2026 earnings: Modern Oral growth lifts sales as spending weighs on profit
Turning Point Brands’ Q2 2026 net sales rose 22.6% to $142.9 million, led by a 128% increase in Modern Oral net sales to $68.4 million. Diluted EPS fell to $0.18 from $0.79, while adjusted EBITDA declined 50.0% to $15.2 million as SG&A nearly doubled amid sales, marketing and freight spending. Reported gross profit benefited from a tariff refund, and the company raised full-year Modern Oral gross and net sales guidance while providing adjusted EBITDA guidance of $70 million to $90 million.
TradingKey
Wed, Aug 5
Cummins Q2 2026 earnings: Power Systems lifts revenue and full-year outlook
Cummins’ Q2 2026 revenue rose 9% year over year to $9.46 billion, while net income attributable to the company increased to $932 million and diluted EPS reached $6.73. Non-GAAP EBITDA rose to $1.65 billion, but its margin fell to 17.5% as higher incentive compensation weighed on profitability. Power Systems led segment growth on data center power demand, operating cash flow nearly doubled to $1.50 billion, and Cummins raised its full-year revenue growth outlook to 10%-13% while increasing the lower end of its EBITDA margin guidance.
TradingKey
Wed, Aug 5
PSEG Q2 2026 earnings: Adjusted profit rises as GAAP income falls
PSEG's Q2 2026 revenue fell about 9% year over year to $2.554 billion, while GAAP diluted EPS declined to $0.67 from $1.17. Non-GAAP operating EPS moved the other direction, rising to $0.86 from $0.77 as PSE&G earnings increased and PSEG Power & Other benefited from higher realized prices and nuclear generation. The company maintained its 2026 non-GAAP operating EPS guidance of $4.28 to $4.40. Investors should monitor market-to-market volatility, rising utility costs, the loss of zero-emission certificate support, and execution of the five-year capital plan.
TradingKey
Wed, Aug 5
Strata Q2 2026 earnings: Clinical expansion lifts revenue and adjusted EBITDA
Strata Critical Medical’s Q2 2026 revenue rose 60.7% to $72.5 million, while adjusted EBITDA increased to $7.9 million with a 10.9% margin. Clinical revenue reached $24.3 million and grew 15.1% sequentially excluding acquisitions completed during the quarter, but the continuing-operations net loss widened to $10.5 million as amortization and noncash earn-out revaluation weighed on GAAP results. The company generated $2.9 million in free cash flow and raised its 2026 revenue and adjusted EBITDA guidance, while Logistics margin pressure remained an important counterweight.
TradingKey
Wed, Aug 5
Tower Semiconductor Q2 2026 earnings: 24% revenue growth drives margin expansion
Tower Semiconductor’s Q2 2026 revenue rose 24% year over year to $460.1 million, while GAAP diluted EPS increased to $0.79 from $0.41. Gross profit climbed 72% to $137.8 million, lifting gross margin to 29.9% from 21.5%, as management cited demand momentum across key businesses and a $680 million SiPho annualized revenue run rate. Operating cash flow improved to $177.0 million, though $186.6 million of capital investment produced negative quarterly free cash flow. The company guided Q3 revenue to a $520 million midpoint.TradingKey
Wed, Aug 5
LGI Homes Q2 2026 Earnings: Revenue Rises as Margins Narrow
LGI Homes reported Q2 2026 total revenue of $516.0 million, up 5.7% year over year, while diluted EPS fell to $1.16 from $1.36. Homebuilding revenue rose 3.7% to $501.5 million on 1,365 closings, but homebuilding gross margin narrowed to 19.8% from 22.9%. The company reduced debt by $128.6 million during the quarter and raised its full-year average sales price and homebuilding margin guidance, while a higher cancellation rate remains an important demand indicator.
TradingKey
Wed, Aug 5
Certara Q2 2026 earnings: Software growth offsets weaker services
Certara’s Q2 2026 continuing-operations revenue rose 1% to $93.3 million, with software revenue up 4% to $48.8 million and services revenue down 3% to $44.5 million. GAAP diluted EPS swung to a $0.04 loss from earnings of $0.01, while adjusted EPS held at $0.08 and adjusted EBITDA declined 3% to $26.2 million. The company reaffirmed 0%-4% full-year revenue growth, outlined approximately $13 million in targeted run-rate savings and completed its previously authorized $100 million repurchase program.
TradingKey
Wed, Aug 5
Arvinas Q2 2026 earnings: Licensing revenue drives a return to profit
Arvinas’ Q2 2026 revenue rose to $249.7 million from $22.4 million, and diluted EPS swung to $2.58 from a $0.84 loss. The turnaround was driven largely by Pfizer collaboration revenue, $62.5 million from the Rigel license agreement, and a $50.0 million FDA approval milestone for VEPPANU. GAAP R&D expense declined to $52.6 million, while cash, cash equivalents, and marketable securities ended June at $567.9 million. Management says the current operating plan is funded into the second half of 2028, with several Phase 1 readouts ahead.
TradingKey
Wed, Aug 5
BellRing Brands Q3 FY2026 earnings: Sales growth came with a sharp margin decline
BellRing Brands reported fiscal Q3 2026 net sales of $570.4 million, up 4.2%, while diluted EPS increased to $0.29 from $0.16. Underlying profitability weakened as adjusted EBITDA fell to $78.3 million from $120.3 million amid input-cost inflation, tariffs, higher freight and a $10 million excess bottle inventory charge. Dymatize sales rose 26.7%, offsetting slower Premier Protein growth. BellRing updated its full-year outlook to $2.335-$2.375 billion in sales and $275-$295 million in adjusted EBITDA, including $28 million of unfavorable inventory-related effects.
TradingKey
Wed, Aug 5
Shoals Q2 2026 earnings: Revenue rises as gross margin contracts
Shoals Technologies Group reported Q2 2026 revenue of $163.4 million, up 47.4% year over year, while diluted EPS fell to $0.07 from $0.08. Gross margin narrowed to 30.3% from 37.2% as the new manufacturing facility ramp, product mix, quality-related work and material inefficiencies raised costs. Adjusted EBITDA increased to $31.6 million, and backlog plus awarded orders reached a record $801.4 million. The company issued Q3 ranges and reaffirmed its full-year 2026 outlook, but first-half cash conversion remains a central issue.
TradingKey
Wed, Aug 5
First Watch Q2 2026 Earnings: Revenue Rises 15.2% as June Traffic Turns Positive
First Watch’s Q2 2026 revenue rose 15.2% to $354.7 million, while diluted EPS increased to $0.04 from $0.03. Same-restaurant sales grew 3.4% even as quarterly traffic remained 0.4% lower, with management noting that traffic turned positive in June. Restaurant-level operating margin improved 20 basis points to 18.8%, but operating margin slipped to 2.3%. The company opened 18 restaurants and updated fiscal 2026 guidance to 12.5%-14.0% revenue growth and $133-$136 million of adjusted EBITDA, while planning 60 to 62 net new system-wide restaurants.
TradingKey
Wed, Aug 5
Superior Group Q2 2026 earnings: Branded Products lifts adjusted profit
Superior Group of Companies’ Q2 2026 net sales rose 2.6% to $147.8 million, while GAAP diluted EPS fell to $0.08 from $0.10 after a $2.6 million non-cash Healthcare Apparel tradename impairment. Excluding the charge, adjusted EPS increased to $0.21 from $0.10 and adjusted EBITDA advanced 26.6% to $7.7 million. Branded Products drove the quarter, offsetting lower sales in Healthcare Apparel and Contact Centers. SGC reaffirmed its 2026 sales and adjusted EPS guidance, with stronger results expected in the second half.
TradingKey
Wed, Aug 5
Rhythm Q2 2026 earnings: IMCIVREE sales rise 47% as SG&A climbs
Rhythm Pharmaceuticals’ Q2 2026 earnings showed net product revenue rising 47% year over year to $71.3 million, with U.S. IMCIVREE revenue reaching $51.0 million as acquired hypothalamic obesity demand accelerated. A French retrospective charge weighed on ex-U.S. sales. SG&A expense increased to $67.4 million from $45.9 million, and net loss attributable to common stockholders widened to $50.4 million even as diluted loss per share narrowed to $0.73. Cash and short-term investments totaled $330.9 million, with management projecting at least 24 months of funding.
TradingKey
Wed, Aug 5
AdaptHealth Q2 2026 Earnings: Revenue Rises as Margins Contract
AdaptHealth (NASDAQ: AHCO) reported Q2 2026 revenue of $740.3 million, up 12.7%, and organic growth of 15.9%. Diluted EPS from continuing operations fell to a $1.07 loss from a $0.03 profit, while adjusted EBITDA declined 3.2% to $132.0 million. A $144.2 million goodwill impairment drove the GAAP loss, and transition costs for a West Coast capitated contract plus a manufacturer price increase pressured margins. The company revised 2026 adjusted EBITDA guidance to $490 million-$520 million as it prepares to divest Diabetes Health for $235 million in cash.
TradingKey
Wed, Aug 5
Featured Tools
Top News
Amazon Shares Plunge 11% After Hours as Q3 Revenue Misses Estimates, Free Cash Flow Negative $33.456 Billion
Amazon Stock Forecast: AMZN Needs a Close Above $258 as Q3 Tests Its AI Spending
Marvell’s Proposed Acquisition of Lumentum Sparks Pre-Market Divergence in Optical Communications Stocks: MRVL Falls Over 11%, LITE Rises Over 4%, COHR Slips 0.63%
The Future of AI 3D Character Workflows: Reallusion CC 5.2 Turns Meshes into Living Characters
Amazon Q3 Earnings Preview: AWS Growth Expected to Rise to 41%, Wall Street Top Price Target $400